Header cover image

U.S. Drug Retail Industry Analysis

UpdatedDec 21, 2024
DataAggregated Company Financials
Companies12
  • 7D-8.0%
  • 3M9.8%
  • 1Y-63.4%
  • YTDn/a

Over the last 7 days, the Drug Retail industry has dropped 5.3%, driven by declines from every company within the industry. The industry has fallen 64% in the last year. Earnings are forecast to grow by 105% annually.

Industry Valuation and Performance

Has the U.S. Drug Retail Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 21 Dec 2024US$9.6bUS$151.0b-US$8,784,148,978.82n/a-1.1x0.06x
Mon, 18 Nov 2024US$8.7bUS$151.0b-US$8,795,001,728.35n/a-1x0.06x
Wed, 16 Oct 2024US$10.2bUS$151.0b-US$8,683,666,870.0876.6x-1.2x0.07x
Fri, 13 Sep 2024US$7.6bUS$147.8b-US$5,892,343,681.45n/a-1.3x0.05x
Sun, 11 Aug 2024US$9.3bUS$147.8b-US$5,884,430,161.58n/a-1.6x0.06x
Tue, 09 Jul 2024US$9.8bUS$147.8b-US$5,905,475,315.83n/a-1.7x0.07x
Thu, 06 Jun 2024US$14.1bUS$146.9b-US$6,131,679,196.69n/a-2.3x0.1x
Sat, 04 May 2024US$15.3bUS$146.9b-US$6,142,350,372.3138.5x-2.5x0.1x
Mon, 01 Apr 2024US$18.9bUS$146.9b-US$6,125,070,448.8635.5x-3.1x0.1x
Wed, 28 Feb 2024US$18.3bUS$144.7bUS$499.5m32.6x36.6x0.1x
Fri, 26 Jan 2024US$19.5bUS$144.8bUS$444.8m35.9x43.8x0.1x
Sun, 24 Dec 2023US$22.9bUS$141.4b-US$3,209,348,662.0050.1x-7.1x0.2x
Tue, 21 Nov 2023US$18.6bUS$164.8b-US$4,844,590,344.0056x-3.8x0.1x
Thu, 19 Oct 2023US$18.7bUS$141.3b-US$3,218,013,505.00361.3x-5.8x0.1x
Sat, 16 Sep 2023US$19.3bUS$138.4b-US$3,448,683,517.00361.3x-5.6x0.1x
Mon, 14 Aug 2023US$25.7bUS$138.3b-US$3,450,626,683.00361.3x-7.5x0.2x
Wed, 12 Jul 2023US$26.8bUS$138.3b-US$3,448,795,973.00n/a-7.8x0.2x
Fri, 09 Jun 2023US$27.8bUS$135.5b-US$3,271,802,295.00n/a-8.5x0.2x
Sun, 07 May 2023US$28.1bUS$135.5b-US$3,266,613,457.00n/a-8.6x0.2x
Tue, 04 Apr 2023US$30.9bUS$135.5b-US$3,264,684,843.00n/a-9.5x0.2x
Thu, 02 Mar 2023US$30.6bUS$134.3b-US$3,076,606,519.00n/a-10x0.2x
Sat, 28 Jan 2023US$32.4bUS$134.3b-US$3,077,362,247.00n/a-10.5x0.2x
Mon, 26 Dec 2022US$33.6bUS$134.7bUS$4.2b7.7x8x0.2x
Wed, 23 Nov 2022US$36.4bUS$134.7bUS$4.2b8.3x8.7x0.3x
Fri, 21 Oct 2022US$29.2bUS$134.7bUS$4.2b6.7x6.9x0.2x
Sun, 18 Sep 2022US$30.0bUS$136.5bUS$5.0b5.8x6x0.2x
Tue, 16 Aug 2022US$35.4bUS$136.6bUS$5.0b6.9x7.1x0.3x
Thu, 14 Jul 2022US$32.5bUS$136.6bUS$5.0b6.3x6.5x0.2x
Sat, 11 Jun 2022US$36.1bUS$138.0bUS$5.8b6.1x6.3x0.3x
Mon, 09 May 2022US$38.3bUS$138.0bUS$5.8b44.8x6.6x0.3x
Wed, 06 Apr 2022US$38.3bUS$162.5bUS$5.6b6.3x6.8x0.2x
Fri, 04 Mar 2022US$41.1bUS$161.4bUS$5.6b6.8x7.3x0.3x
Sun, 30 Jan 2022US$44.4bUS$161.4bUS$5.6b7.3x7.9x0.3x
Tue, 28 Dec 2021US$44.9bUS$158.9bUS$1.6b22x27.3x0.3x
Price to Earnings Ratio

27.3x


Total Market Cap: US$44.9bTotal Earnings: US$1.6bTotal Revenue: US$158.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Drug Retail Industry Price to Earnings3Y Average 2.9x202220232024
Current Industry PE
  • Investors are pessimistic on the American Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading close to its 3-year average PS ratio of 0.18x.
Past Earnings Growth
  • Total earnings for the Drug Retail industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does U.S. Drug Retail compare with similar industries?

US Market-2.39%
Consumer Staples-2.82%
Food and Staples Retail-2.66%
Drug Retail-7.97%
Big Box Super Stores-2.55%
Food Retail-2.68%
Food Distributors-3.87%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
YI 111US$0.886.0%
+US$4.2m
-39.7%PS0.04x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

MGRX

US$2.48

Mangoceuticals

7D

-5.0%

1Y

-43.0%

GRDN

US$21.41

Guardian Pharmacy Services

7D

-7.9%

1Y

n/a

YI

US$0.88

111

7D

6.0%

1Y

-39.7%

MDVL

US$1.80

MedAvail Holdings

7D

-40.6%

1Y

-90.3%